Platelet to lymphocyte ratio as a novel prognostic tool for gallbladder carcinoma

Table 1 Basic characteristics of gallbladder carcinoma patients stratified according to serum level of platelet to lymphocyte ratio

Variable	Overall(n = 316)	PLR < 117.7(n = 100)	PLR≥117.7(n = 216)	P value
Age (yr)	65 (30-87)	65 (43-87)	64 (30-87)	0.1551
Men/Women	101/215	39/61	62/154	0.0681
Gallstone/No	160/156	50/50	110/106	0.8781
Diabetes/No	30/286	10/90	20/196	0.8351
Hypertension/No	57/259	19/81	38/178	0.7621
PLT (109/L)	184 (37-525)	139 (37-261)	216 (37-525)	< 0.0012
Lymphocytes (109/L)	1.3 (0.3-3.5)	1.6 (0.4-3.5)	1.1 (0.2-2.9)	< 0.0012
PLR	152.4 (13.8-2282.6)	93.6 (13.8-117.6)	185.5 (117.9-2282.6)	< 0.0012
WBC (109/L)	6.2 (1.6-33.4)	5.6 (1.9-33.4)	6.6 (1.6-23.4)	0.0132
Neutrophils (109/L)	4.2 (1.0-25.9)	3.4 (1.0-25.9)	4.6 (1.0-19.3)	< 0.0012
CEA (ng/mL)	3.6 (0.5-264.8)	3.8 (1.0-90.6)	3.6 (0.5-264.8)	0.8472
	(n = 168)	(n = 44)	(n = 124)
AFP (ng/mL)	2.9 (1.1-615.4)	3.0 (1.1-53.0)	2.8 (1.1-615.4)	0.7632
	(n = 150)	(n = 36)	(n = 114)
CA-125 (U/mL)	30.8 (6.1-3684)	21.0 (6.1-345.6)	36.5 (6.5-3684.0)	0.0042
	(n = 146)	(n = 41)	(n = 105)
CA-199 (U/mL)	100.5 (0.5-10000)	99.6 (0.5-4306)	125.0 (0.5-10001)	0.3842
	(n = 158)	(n = 45)	(n = 113)
TNM stage I/II/III/IVA/IVB	5/24/59/121/107	4/12/21/36/27	1/12/38/85/80	0.0191
Differentiation:	26/134/156	13/48/39	13/86/117	0.0311
high/moderate/low
Survival time (mo)	9 (1-97)	12 (1-77)	8 (1-97)	< 0.0012
Death/No	254/62	71/29	183/33	0.0041

¹χ² test;

²Wilcoxon test. The values are expressed as the median (range) or number. PLR: Platelet to lymphocyte ratio; PLT: Platelet count; WBC: White blood cell count; CEA: Carcinoembryonic antigen; AFP: Alpha-fetoprotein.